Evidence map›Paper›PMID 24231251›Full record

Trial reportCancer epidemiology2013

Telomere length and risk of glioma.

Farzana Walcott, Preetha Rajaraman, Shahinaz M Gadalla, Peter D Inskip, Mark P Purdue, Demetrius Albanes, Esther Orr, Immaculata De Vivo, Sharon A Savage

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Cancer epidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Farzana WalcottCancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, United States.
Preetha Rajaraman
Shahinaz M Gadalla
Peter D Inskip
Mark P Purdue
Demetrius Albanes
Esther Orr
Immaculata De Vivo
Sharon A Savage
National Institutes of Health · USNational Cancer Institute · USBrigham and Women's Hospital · USHarvard University · US

Funding

Studies of Populations Exposed to Occupational Sources of RadiationZIACP010133 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KITAHARA, CARI · 2009 to 2025
$34.2M
PROSTATE, LUNG, COLORECTAL, &OVARIAN CANCER SCREENINGN01CN025476 · CN · WESTAT, INC. · PI O'BRIEN, BARBARA B · 1992 to 2000
$7.9M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025512 · CN · HENRY FORD HEALTH SYSTEM · PI DEMERS, RAYMOND Y · 1992 to 2001
$2.0M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN075022 · CN · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N. · 1997 to 2001
$1.6M
PROSTATE, LUNG, COLORECTAL &OVARIAN (PLCO) CANCERN01CN025516 · CN · WASHINGTON UNIVERSITY · PI ANDRIOLE, GERALD LOUIS · 1992 to 2001
$1.5M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025524 · CN · UNIVERSITY OF UTAH · PI BUYS, SAUNDRA S · 1992 to 2000
$1.5M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025514 · CN · UNIVERSITY OF COLORADO DENVER · PI CRAWFORD, E DAVID · 1992 to 2000
$1.3M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025515 · CN · PACIFIC HEALTH RESEARCH INSTITUTE · PI YOKOCHI, LANCE L · 1992 to 2000
$1.2M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025511 · CN · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WEISSFELD, JOEL L · 1992 to 2000
$1.2M
PROSTATE, LUNG, COLORECTAL &OVARIAN CANCERN01CN025522 · CN · GEORGETOWN UNIVERSITY · PI GELMANN, EDWARD P · 1992 to 2000
$817k
PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCERN01CN025404 · CN · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S · 1992 to 2000
$584k
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025513 · CN · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CHURCH, TIMOTHY ROBERT · 1992 to 2001
$409k
Intramural NIH HHS ZIA CP010133NCI NIH HHS N01 CN025404NCI NIH HHS N01 CN025476NCI NIH HHS N01 CN025511NCI NIH HHS N01 CN025512NCI NIH HHS N01 CN025513NCI NIH HHS N01 CN025514NCI NIH HHS N01 CN025515NCI NIH HHS N01 CN025516NCI NIH HHS N01 CN025518NCI NIH HHS N01 CN025522NCI NIH HHS N01 CN025524NCI NIH HHS N01 CN075022
6 · The paper itself

Abstract

backgroundTelomere length in blood or buccal cell DNA has been associated with risk of various cancers. Glioma can be a highly malignant brain tumor and has few known risk factors. Genetic variants in or near RTEL1 and TERT, key components of telomere biology, are associated with glioma risk. Therefore, we evaluated the association between relative telomere length (RTL) and glioma in a prospective study. MATERIALS AND

methodsWe performed a nested case-control study within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. RTL was determined by quantitative PCR on blood or buccal cell DNA obtained at least 2 years prior to diagnosis from 101 individuals with glioma cases. Healthy controls (n=198) were matched to cases (2:1) on age, gender, smoking status, calendar year, and DNA source. Conditional logistic regression was used to investigate the association between RTL and glioma.

resultsAs expected, RTL declined with increasing age in both cases and controls. There was no statistically significant association between RTL and glioma overall. An analysis stratified by gender suggested that short RTL (1st tertile) in males was associated with glioma (odds ratio, [OR]=2.29, 95% confidence interval [CI] 1.02-5.11); this association was not observed for females (OR=0.41, 95% CI 0.14-1.17).

conclusionsThis prospective study did not identify significant associations between RTL and glioma risk, but there may be gender-specific differences. Larger, prospective studies are needed to evaluate these findings.

Indexed as

AgedCase-Control StudiesDNAFemaleFollow-Up StudiesGliomaHumansMaleMiddle AgedPolymerase Chain ReactionPrognosisProspective StudiesRisk FactorsTelomere HomeostasisDNA95% confidence intervalCancer riskCIEpidemiologyGliomaodds ratioORPLCOProstate, Lung, Colorectal, and Ovarian Cancer Screening TrialQpcrquantitative PCRrelative telomere lengthRTLTelomere length

Identifiers

PMID24231251
PMCPMC3933265
OpenAlexW2078504098

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.